Corporate Snapshot

BELLUS Health Inc. ("BELLUS Health" or "the Company") is a global health company focused on the research and development of innovative health solutions for critical, unmet medical needs. The Company's pharmaceutical pipeline targets disorders for which there are no known cures. BELLUS Health's most advanced pharmaceutical candidate is KIACTA (eprodisate) to treat Amyloid A (AA) amyloidosis, a disease marked by an abnormal accumulation of certain proteins that can cause organ dysfunction, organ failure, and even death. In December 2010, KIACTA entered a confirmatory Phase III trial funded by Celtic Therapeutics, a global private equity firm, under an April 2010 agreement between BELLUS Health and Celtic. The Company's pipeline also includes NRM8499, a prodrug for Alzheimer's disease (AD) that completed a Phase I trial in January 2011. Additionally, the Company is working to establish a global distribution network for a clinically tested nutraceutical, VIVIMIND (tramiprosate/homotaurine), which is designed to protect memory function. VIVIMIND is approved for sale in Canada, Italy, and Spain and has distributors in Italy, Canada, and the Middle East.

* The Corporate Snapshot was last updated on July 13, 2011.

Latest Research

Quarterly
Update

2011-07-13

Click to View

Executive
Informational
Overview

2010-12-16

Click to View

Stock Information (BLU-TSX)